These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2455592)

  • 21. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination nonviral cytokine gene therapy for head and neck cancer.
    Li D; Zeiders JW; Liu S; Guo M; Xu Y; Bishop JS; O'Malley BW
    Laryngoscope; 2001 May; 111(5):815-20. PubMed ID: 11368072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
    Ishii T; Marumo K
    Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
    Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
    Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo tumor immunotherapy by a bacterial superantigen.
    Ochi A; Migita K; Xu J; Siminovitch K
    J Immunol; 1993 Sep; 151(6):3180-6. PubMed ID: 8376773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo.
    Gill I; Agah R; Hu E; Mazumder A
    Cancer Res; 1989 Oct; 49(19):5377-9. PubMed ID: 2788499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
    Leon JA; Mesa-Tejada R; Gutierrez MC; Estabrook A; Greiner JW; Schlom J; Fisher PB
    Anticancer Res; 1989; 9(6):1639-47. PubMed ID: 2516715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
    Kemp JD; Cardillo T; Stewart BC; Kehrberg E; Weiner G; Hedlund B; Naumann PW
    Cancer Res; 1995 Sep; 55(17):3817-24. PubMed ID: 7641199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
    Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
    Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.
    Berinstein N; Starnes CO; Levy R
    J Immunol; 1988 Apr; 140(8):2839-45. PubMed ID: 3258621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Time-dependent cytotoxic action of human recombinant alpha-interferon (Ro22-8181) in vitro and the sensitivity of various cultured leukemia and lymphoma cell lines to it.
    Shibata T; Shimada Y; Shimoyama M
    Jpn J Clin Oncol; 1985 Mar; 15(1):67-75. PubMed ID: 3981816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Constitutive production of lymphokines by cloned murine B-cell lymphomas--CH12 B lymphoma produces interleukin-4.
    O'Garra A; Barbis D; Harada N; Lee F; Howard M
    J Mol Cell Immunol; 1989; 4(3):149-58; discussion 158-9. PubMed ID: 2788429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
    Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
    J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific enhancement of drug delivery to AKR lymphoma by antibody-targeted small unilamellar vesicles.
    Matthay KK; Heath TD; Papahadjopoulos D
    Cancer Res; 1984 May; 44(5):1880-6. PubMed ID: 6713389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.